Core Insights - The participation of Sichuan's biopharmaceutical companies in the 2025 World Pharmaceutical Raw Materials Europe Exhibition marks a significant step towards integrating into the global industrial chain [1][3] - Sichuan's exhibition area exceeds 900 square meters, ranking among the top in China's exhibition groups [2] - The delegation consists of 73 local pharmaceutical and related enterprises, with over 150 participants showcasing key products such as specialty raw materials, high-end medical devices, and innovative biopharmaceuticals [1][2] Industry Overview - The World Pharmaceutical Raw Materials Europe Exhibition is the largest and most influential event in the pharmaceutical industry, attracting over 2,500 exhibitors from more than 140 countries and regions [1][2] - The exhibition focuses on green pharmaceuticals and biomanufacturing, aligning well with the development direction of Sichuan's biopharmaceutical industry [2][3] Company Highlights - Notable companies participating include Sichuan Kelun Pharmaceutical, Chengdu Kanghua Biological Products, and Chengdu Beite Pharmaceutical, covering the entire biopharmaceutical industry chain in Sichuan [3] - Sichuan Xinmeijia Biopharmaceutical Co., Ltd. is the largest fish oil producer in China, with significant orders expected during the exhibition, including a projected 30 million yuan in contracts [4] - Chengdu Okang Pharmaceutical Co., Ltd., listed on the Beijing Stock Exchange, is expanding from health food and food additives into the raw materials market [4] Strategic Goals - The event is part of the "Chuanxing Tianxia" international market expansion initiative, aiming to showcase Sichuan's innovative strength and development vitality in the biopharmaceutical sector [1][3] - The strategy emphasizes building networks and strengthening supply chains to enhance international order acquisition and promote high-quality industry development [4]

Group 1: New Listings - On July 14-20, one company listed on the Shanghai Stock Exchange main board, while no companies listed on the Shenzhen Stock Exchange [2] - China Huadian New Energy, focused on wind and solar power generation, saw its stock price rise over 125.79% on its first trading day, closing at 7.56 CNY per share, a 137.74% increase from the issue price of 3.18 CNY, with a total market capitalization of approximately 309.7 billion CNY [3] Group 2: Companies Passing Review - One company passed the review on the Shanghai Stock Exchange's Sci-Tech Innovation Board during the same period, while no companies passed on the Shenzhen Stock Exchange [4] - Shenzhen Beixin Life Technology Co., Ltd. specializes in innovative medical devices for cardiovascular disease diagnosis and treatment [5] Group 3: Terminated Listing Reviews - No companies terminated their listing reviews on the Shanghai Stock Exchange during this period, while one company on the Shenzhen Stock Exchange main board and one on the ChiNext did [7] - Guangdong Zhengyang Sensor Technology Co., Ltd. in the automotive manufacturing industry and Guizhou Duocai New Media Co., Ltd. in telecommunications both terminated their listing reviews [8] Group 4: Hong Kong Stock Exchange Activities - No new companies listed on the Hong Kong Stock Exchange during July 14-20 [9] - Three companies submitted applications for main board listings: Hunan Maijizhi Biotechnology Co., Ltd., Aux Electric Co., Ltd., and Shanghai Zhida Technology Development Co., Ltd. [12][13] - Hunan Maijizhi is a clinical-stage biopharmaceutical company focused on innovative biological agents for allergic and autoimmune diseases [14] - Aux Electric is one of the top five air conditioning providers globally, with a market share of 7.1% as of 2024 [16] - Shanghai Zhida Technology is the largest supplier of home electric vehicle charging solutions globally [19] Group 5: Financial Data and Fundraising - Hunan Maijizhi reported revenues of 8.72 million CNY and a net loss of 253 million CNY for 2023, with projections for 2024 showing a revenue of 2.4 million CNY and a net loss of 178 million CNY [14] - Aux Electric's revenues are projected to grow from 19.528 billion CNY in 2022 to 29.759 billion CNY in 2024, with net profits increasing from 1.442 billion CNY to 2.910 billion CNY [16] - Shanghai Zhida's revenues are expected to decline from 697 million CNY in 2022 to 593 million CNY in 2024, with net losses increasing from 25.147 million CNY to 236 million CNY [21]